Clinical trial NCT06005051: Prediabetes Stratification by Multi-omics Profile After Food Intake
Official title: Prediabetes Stratification by Multi-omics Profile After Food Intake
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Diabetes Mellitus, Type 2
PreDiabetes
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-08-22
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All participants will consume the meals using the cgm and fitbit devices and log their meal intake.
Primary purpose: TREATMENT

Brief summary: 1 in 3 adults have prediabetes in the United States, and many of them will eventually develop diabetes, which has significant public health and economic costs. However, type 2 diabetes (T2D) and prediabetes are heterogeneous groups with different pathological mechanisms, dysfunctions in different processes, and varied disease trajectories. Patient stratifications into subtypes and personalized nutrition interventions are highly needed but not yet available. Metabolic responses (e.g., glucose excursion) after food intake provide a direct observation of personal metabolic control and its association with T2D.

The investigators hope to learn how prediabetes and type 2 diabetes evolve, and specifically what food or exercise can do to mitigate blood sugar response.

Detailed description: Screening: The investigators will check fasting blood sugars, HbA1C to determine status (healthy, prediabetes or diabetes).

Enrolled participants will be provided with a Continuous Glucose Monitor (CGM) to measure blood sugars for 10 days and a Fitbit fitness tracker. They will then follow the instructions for each of the 10 days on the monitors:

Day 0: participants will start using the devices and start recording food intake in a food logging app (Cronometer) Day 1-6: Participants will eat a provided portion of white rice (50g of carbohydrates) within 1.5 hrs of waking up). Day 1,3, 5 consume one of the mitigator foods provided (fat (cream), protein (egg whites), or fiber (powdered pea fiber)). Days 2 and 4 no mitigators will be consumed. Day 6 the investigators will ask participants to exercise before eating the rice. Exercise will be moderate for 20 min with constant heart rate level about (220-age)\*0.7. During these 6 days participants will be asked to collect microsamples of blood using the Tasso device on the following time points: right after waking up; right before eating their rice; 30 minutes, 1, 2 and 3 hours after the start of the rice meal; right before going to bed

Days 7-9 no intervention, just continue to use devices and log food intake.

Optional- 5 participants who volunteer to repeat this 10 day cycle 3 times.

Optional metabolic tests:

1. Oral Glucose Tolerance Test (OGTT) to measure glucose tolerance and beta cell function: participants will be provided with a 75g glucose solution to drink and collect samples at 10-30min intervals for 180 minutes.
2. Undergo an insulin sensitivity test (Steady State Plasma Glucose, SSPG)- glucose, insulin and ocreotide infusions will be provided and blood samples taken at 10-30min intervals for 240 min.
3. Undergo an Isoglycemic Intravenous Glucose Infusion test (IIGI) to test for incretin hormone function- a glucose infusion will be given and blood samples collected at 10-30 min intervals for 180 min.

Eligibility criteria: Inclusion Criteria:

* Be 18 years of age or older;
* Not be pregnant;
* Live close to Stanford Campus
* Be generally healthy (with no apparent symptoms at the time of enrollment)
* Patients with prediabetes or diet-controlled or type 2 diabetes or controlled with metformin, will also be allowed to participate.
* Be willing to provide written informed consent for all study procedures.-

Exclusion Criteria:

* Major organ diseases,
* Pregnant or lactating. If a participant will become pregnant while in the study, she will be removed from the study.
* are on diabetogenic medications (with the exclusion of metformin),
* have malabsorptive disorders like celiac sprue or similar
* report heavy alcohol use,
* use of weight loss medications or specific diets,
* weight change \> 2 kg in the last three weeks,
* history of bariatric surgery
* Any medical condition that our physician believes would interfere with study participation or evaluation of results.
* Mental incapacity and/or cognitive impairment on the part of the patient that would preclude the adequate understanding of, or cooperation with, the study protocol.

Primary outcomes:
measure: Comparison of blood glucose levels after the different dietary and exercise mitigators
timeFrame: 10 days
measure: Changes in postprandial metabolites response as measured by micro-sampling
timeFrame: 10 days
Secondary outcomes:
measure: Changes in postprandial proteomic responses as measured in micro-sampling by Olink
timeFrame: 10 days
measure: Changes in personal metabolic states through the day as measured in micro-sampling by targeted and untargeted metabolomics (LC-MS)
timeFrame: 10 days
measure: Changes in personal metabolic states through the day as measured in micro-sampling by Olink proteomics
timeFrame: 10 days
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Stanford University
name: Yue Wu, PhD
role: STUDY_DIRECTOR
References: